Impact of JAK Inhibitors on Itch and Quality of Life in Atopic Dermatitis

EP: 1.Quality of Life in Patients with Atopic Dermatitis and Patient-Reported Outcomes

EP: 2.Atopic Dermatitis Treatment Advances and Changing Quality of Life Expectations

Now Viewing

EP: 3.Impact of JAK Inhibitors on Itch and Quality of Life in Atopic Dermatitis

EP: 4.TARGET-DERM: A Real-World Study of Patient-Reported Outcomes in Atopic Dermatitis

EP: 5.Durability of Effect and Advice to Improve Quality of Life in Atopic Dermatitis

Video content above is prompted by the following questions:

• What characteristics, if any, of oral JAK inhibitors make them an attractive option for improving QoL in patients with AD?
• Discuss clinical trial data with oral JAK inhibitors, upadacitinib and abrocitinib, and improvements in patient-reported outcomes in atopic dermatitis.
  • Please review data from real-world studies that have evaluated effectiveness of oral JAK inhibitors (upadacitinib and abrocitinib) through physician and patient-reported outcomes.